The role of radiation in treating non-malignant diseases is currently undergoing an American Renaissance. Low-dose radiation therapy (LDRT) has been used successfully throughout the world for treating benign conditions for over a century, but its resurgence has been...
Xstrahl's Medical Director, Dr. Richard Shaffer, recently spoke for a webinar hosted by Joint Pain Practice. He shares how low-dose radiotherapy can be used for osteoarthritis, and overviews the treatment process, risks, and efficacy. https://youtu.be/ab4iyfhN_L8...
In this webinar, Tom Murray of Hull University Teaching Hospitals presents on developing an internal eye shield for radiotherapy. Internal eye shields are a simple yet effective solution to protect the patient’s lenses during superficial and orthovoltage radiation...
This webinar, with presentations in both Spanish and English, provides an overview and history of radiotherapy for benign conditions as well as radiotherapy for osteoarthritis. https://vimeo.com/905279833
Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
The Dermatology Insider 2023 is Xstrahl’s magazine for dermatologists. This issue of the Dermatology Insider includes patient stories about having SRT treatment for their skin cancer. In addition, hear from a dermatologist as he describes his experience using radiation therapy to treat non-melanoma skin cancer (NMSC). See two case history reports of radiation therapy treatment for skin cancer using SRT and eBt, detailing the number of treatments, dose per treatment, reasons for radiation therapy, as well as before and after images of the results. Xstrahl introduces Radiant Aura, which recently received US Food & Drug Administration (FDA) 510(k) Clearance. We share more about using Radiant Aura and answer the most commonly asked questions in our FAQ section.
Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance
Expands office-based treatment options for millions of non-melanoma skin cancer (NMSC) patients
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, announced its Radiant™ Aura treatment solution has received U.S. Food and Drug Administration (FDA) 510(k) clearance. With advanced features for expanded clinical use, simplified patient positioning, and additional patient comfort, Radiant Aura brings radiation therapy to NMSC patients in any dermatology office.
In this case, Xstrahl 100 was used to treat a keloid scar on an earlobe that developed from an ear piercing.
Dr. Sean E. Mazloom, MD, FAAD, from ReJUVA Dermatology, Vein & Skin Cancer Center, Venice, FL has been using the RADiant system to treat both squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) in his practice. Depending on a number of factors specific to each patient, he has treated these conditions with superficial radiation therapy (SRT) and electronic brachytherapy (eBT). Below are two case studies that describe the treatment process and results.
Contact Us